0.000High0.000Low0Volume0.000Open0.000Pre Close0.00Turnover0.00%Turnover Ratio0.00P/E (Static)50.07MShares76.01052wk High0.00P/B0Float Cap75.30052wk Low--Dividend TTM48.20MShs Float141.300Historical High--Div YieldTTM0.00%Amplitude23.770Historical Low--Avg Price1Lot Size
Turning Point Therapeutics Stock Forum
ColumnsTop upgrades and downgrades on 6/6
• $Ardagh Metal(AMBP.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $9
• $American Express(AXP.US)$ : Edward Jones Upgrades to Buy from Hold
• $CrowdStrike(CRWD.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $215 (from $195)
• $Lululemon Athletica(LULU.US)$ : Bernstein Upgrades to Market Perform from Underperform - PT $300 (from $260)
• $ResMed(RMD.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $244 (from $...
ColumnsToday's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more
• $Okta(OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
ColumnsTop upgrades and downgrades on 5/20
• $Banco De Chile(BCH.US)$ : Santander Upgrades to Outperform from Neutral - PT $25
• $Comerica(CMA.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Mirati Therapeutics(MRTX.US)$ : Guggenheim Upgrades to Buy from Neutral - PT $115
• $Ollie's Bargain Outlet(OLLI.US)$ : BofA Securities Upgrades to Buy from Underperform - PT $75 (from $39)
• $Trex Co.(TREX.US)$ : Exane Upgrades to Neutral from Underperform - PT $75
Downgrades
• $Ferguson(FERG.US)$ : Exane D...
$E-Home Household Service(EJH.US)$ E-Home Household Service Holdings Limited Enters Into Two Separate Equity Acquisition Agreements To Acquire Significant Stakes In Household Appliance Service And Property Management Firms
$Turning Point Therapeutics(TPTX.US)$ Oppenheimer Maintains Outperform on Turning Point, Lowers Price Target to $105
No comment yet